Raymond James Financial Inc. Acquires Shares of 112,771 Glaukos Co. (NYSE:GKOS)

Raymond James Financial Inc. acquired a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 112,771 shares of the medical instruments supplier's stock, valued at approximately $16,910,000. Raymond James Financial Inc. owned about 0.20% of Glaukos as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of GKOS. IFP Advisors Inc purchased a new stake in shares of Glaukos during the fourth quarter valued at $43,000. Asset Planning Inc acquired a new stake in Glaukos during the 4th quarter worth about $90,000. Picton Mahoney Asset Management purchased a new stake in Glaukos during the fourth quarter valued at about $125,000. SBI Securities Co. Ltd. acquired a new position in shares of Glaukos in the fourth quarter worth about $153,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Glaukos by 275.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after acquiring an additional 807 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several research analyst reports. Stifel Nicolaus lifted their price objective on shares of Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Needham & Company LLC increased their price objective on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Truist Financial decreased their price objective on Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Wells Fargo & Company increased their price target on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $156.17.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Stock Performance

GKOS traded up $2.12 during trading on Thursday, hitting $94.73. The stock had a trading volume of 358,227 shares, compared to its average volume of 886,203. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $77.91 and a 12 month high of $163.71. The company has a 50 day simple moving average of $104.65 and a 200-day simple moving average of $130.56. The firm has a market cap of $5.36 billion, a PE ratio of -33.01 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.